IL6 and cancer: Oclacitinib, an FDA-approved JAK inhibitor for the treatment of atopic dermatitis in dogs, blocks IL-6 signaling and subsequent STAT3 phosphorylation at recommended dosing [16], thus represents a viable approach to targeting STAT3 in veterinary cancer patients.